Product Images Nilotinib
View Photos of Packaging, Labels & Appearance
- nilotinib150mgwalletcarton - nilotinib150mgwalletcarton
- nilotinib150mgwalletpack - nilotinib150mgwalletpack
- nilotinib200mgwalletcarton - nilotinib200mgwalletcarton
- nilotinib200mgwalletpack - nilotinib200mgwalletpack
- nilotinibcamberlogo - nilotinibcamberlogo
- nilotinibchemicalstructure - nilotinibchemicalstructure
- nilotinibfigure1 - nilotinibfigure1
- nilotinibfigure2 - nilotinibfigure2
Product Label Images
The following 8 images provide visual information about the product associated with Nilotinib NDC 31722-780 by Camber Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
nilotinib150mgwalletcarton - nilotinib150mgwalletcarton
This text provides information about Nilotinib Capsules, emphasizing the importance of taking them on an empty stomach. It includes details about the dosage, storage instructions, and contact information for the manufacturer. The medication guide must be dispensed to each patient, and the capsules come in a child-resistant package containing 4 individual blister packs, each with 28 capsules.*
nilotinib200mgwalletcarton - nilotinib200mgwalletcarton
This text provides detailed information about Nilotinib Capsules, including dosage instructions, storage guidelines, and manufacturer details. It highlights the importance of taking the capsules on an empty stomach and avoiding food before and after intake. The pack contains 4 blister packs, each with 28 capsules. The medication is for oral use and each capsule contains 200mg of nilotinib. The package is child-resistant and the medication guide should be dispensed separately to each patient. Remember to store the capsules at 20° to 25°C.*
nilotinibfigure1 - nilotinibfigure1
This text provides information about a study or analysis involving therapy cessation and censored observations. It includes data points related to the time when therapy was discontinued and the time since the therapy-free interval. The text also mentions specific time intervals and percentages, which may be important for conducting further analysis.*
nilotinibfigure2 - nilotinibfigure2
This data shows the Treatment-free survival (%) over time since treatment. It includes information on the number of observations, censoring, and the time in weeks since treatment-free survival.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.